Price
$1.87
Increased by +1.63%
Dollar volume (20D)
5.91 M
ADR%
7.50
Earnings report date
Mar 12, 2025
Shares float
151.87 M
Shares short
31.17 M [20.52%]
Shares outstanding
209.67 M
Market cap
385.80 M
Beta
0.84
Price/earnings
N/A
20D range
1.78 2.77
50D range
1.78 3.36
200D range
1.78 5.78

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer.

It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).

The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia.

In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer.

The company has license and collaboration agreements with Pfizer Inc.; Servier; CellectisS. A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3.

The company was incorporated in 2017 and is headquartered in South San Francisco, California.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Nov 7, 24 -0.32
Increased by +13.51%
-0.33
Increased by +3.03%
Aug 7, 24 -0.35
Increased by +33.96%
-0.35
May 13, 24 -0.38
Increased by +44.12%
-0.41
Increased by +7.32%
Mar 14, 24 -0.43
Increased by +34.85%
-0.45
Increased by +4.44%
Nov 2, 23 -0.37
Increased by +36.21%
-0.52
Increased by +28.85%
Aug 2, 23 -0.53
Decreased by -1.92%
-0.59
Increased by +10.17%
May 3, 23 -0.68
Decreased by -21.43%
-0.62
Decreased by -9.68%
Feb 28, 23 -0.66
Decreased by -22.22%
-0.70
Increased by +5.71%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 24 0.00
Decreased by -100.00%
-66.29 M
Decreased by -8.12%
Decreased by N/A%
Decreased by N/A%
Jun 30, 24 0.00
Decreased by -100.00%
-66.36 M
Increased by +14.91%
Decreased by N/A%
Decreased by N/A%
Mar 31, 24 22.00 K
Decreased by -57.69%
-65.00 M
Increased by +33.90%
Decreased by -295.45 K%
Decreased by -56.23%
Dec 31, 23 21.00 K
Decreased by -55.32%
-85.78 M
Increased by +8.08%
Decreased by -408.47 K%
Decreased by -105.72%
Sep 30, 23 43.00 K
Decreased by -12.24%
-61.31 M
Increased by +25.36%
Decreased by -142.59 K%
Increased by +14.94%
Jun 30, 23 44.00 K
Decreased by -48.84%
-77.99 M
Decreased by -4.72%
Decreased by -177.25 K%
Decreased by -104.69%
Mar 31, 23 52.00 K
Decreased by -14.75%
-98.34 M
Decreased by -23.37%
Decreased by -189.11 K%
Decreased by -44.73%
Dec 31, 22 47.00 K
Decreased by -7.84%
-93.32 M
Decreased by -24.65%
Decreased by -198.55 K%
Decreased by -35.25%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY